Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABX 002

Drug Profile

ABX 002

Alternative Names: ABX-002

Latest Information Update: 03 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Autobahn Therapeutics
  • Class Acetamides; Antidepressants; Behavioural disorder therapies; Neuroprotectants; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bipolar depression; Major depressive disorder
  • Preclinical Adrenomyeloneuropathy
  • Research Multiple sclerosis

Most Recent Events

  • 29 May 2024 Phase-I clinical trials in Bipolar depression (Adjunctive treatment) (PO) prior to May 2024
  • 07 Nov 2023 Pharmacokinetics and adverse event data from a phase I trial in Major depressive disorder released by Autobahn Therapeutics
  • 13 Sep 2023 Autobahn Therapeutics completes a phase I trial in Major depressive disorder (Adjunctive treatment) in Australia (PO, Liquid) (NCT05528315)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top